Mark Plavsic
Chief Tech/Sci/R&D Officer bei AURA BIOSCIENCES, INC.
Vermögen: 2 Mio $ am 31.03.2024
Profil
Dr. Mark Plavsic ist ein Chief Technical Officer bei Fate Therapeutics, Inc. Dr. Plavsic war zuvor als Chief Technical Officer bei Lysogene SA und als Head- Process Development & Manufacturing bei Torque Therapeutics, Inc. beschäftigt. Er erhielt seinen Abschluss an der Universität von Belgrad und promovierte an der Universität von Belgrad.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
AURA BIOSCIENCES INC
0,26% | 15.03.2024 | 128 515 ( 0,26% ) | 1 Mio $ | 31.03.2024 |
FATE THERAPEUTICS, INC.
0,12% | 10.01.2023 | 123 705 ( 0,12% ) | 907 995 $ | 31.03.2024 |
Aktive Positionen von Mark Plavsic
| Unternehmen | Position | Beginn |
|---|---|---|
| AURA BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 02.10.2023 |
TeraPore Technologies, Inc.
 TeraPore Technologies, Inc. Chemicals: SpecialtyProcess Industries TeraPore Technologies, Inc. develops cutting-edge membrane technologies for high-permeability, high-resolution nanofiltration. The company was founded by Rachel Dorin in 2013 and is headquartered in | Director/Board Member | - |
Ehemalige bekannte Positionen von Mark Plavsic
| Unternehmen | Position | Ende |
|---|---|---|
| FATE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 06.03.2023 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Torque Therapeutics, Inc.
 Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
| LYSOGENE | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Mark Plavsic
| University of Belgrade | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| AURA BIOSCIENCES, INC. | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| LYSOGENE | Commercial Services |
| Private Unternehmen | 3 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | Health Technology |
TeraPore Technologies, Inc.
TeraPore Technologies, Inc. Chemicals: SpecialtyProcess Industries TeraPore Technologies, Inc. develops cutting-edge membrane technologies for high-permeability, high-resolution nanofiltration. The company was founded by Rachel Dorin in 2013 and is headquartered in | Process Industries |
